Standard-of-care chemotherapy

AUG 13, 2026 · PHASE 1/2 TRIAL

Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy

ClinicalTrials.gov

This is a Phase 1/2 registry record for a planned study with no reported results; enrollment is estimated at only 10 participants across a safety lead-in and randomized cohort, making it an early-stage feasibility and safety assessment.